Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease

Leuzy, Antoine LU ; Bollack, Ariane ; Pellegrino, Daniela ; Teunissen, Charlotte E. ; La Joie, Renaud ; Rabinovici, Gil D. ; Franzmeier, Nicolai LU ; Johnson, Keith ; Barkhof, Frederik and Shaw, Leslie M. , et al. (2025) In Alzheimer's and Dementia 21(3).
Abstract

Amyloid-β (Aβ) positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) biomarkers are now established tools in the diagnostic workup of patients with Alzheimer's disease (AD), and their use is anticipated to increase with the introduction of new disease-modifying therapies. Although these biomarkers are comparable alternatives in research settings to determine Aβ status, biomarker testing in clinical practice requires careful consideration of the strengths and limitations of each modality, as well as the specific clinical context, to identify which test is best suited for each patient. This article provides a comprehensive review of the pathologic processes reflected by Aβ-PET and CSF biomarkers, their performance, and... (More)

Amyloid-β (Aβ) positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) biomarkers are now established tools in the diagnostic workup of patients with Alzheimer's disease (AD), and their use is anticipated to increase with the introduction of new disease-modifying therapies. Although these biomarkers are comparable alternatives in research settings to determine Aβ status, biomarker testing in clinical practice requires careful consideration of the strengths and limitations of each modality, as well as the specific clinical context, to identify which test is best suited for each patient. This article provides a comprehensive review of the pathologic processes reflected by Aβ-PET and CSF biomarkers, their performance, and their current and future applications and contexts of use. The primary aim is to assist clinicians in making better-informed decisions about the suitability of each biomarker in different clinical situations, thereby reducing the risk of misdiagnosis or incorrect interpretation of biomarker results. Highlights: Recent advances have positioned Aβ PET and CSF biomarkers as pivotal in AD diagnosis. It is crucial to understand the differences in the clinical use of these biomarkers. A team of experts reviewed the state of Aβ PET and CSF markers in clinical settings. Differential features in the clinical application of these biomarkers were reviewed. We discussed the role of Aβ PET and CSF in the context of novel plasma biomarkers.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer, Aβ-PET, biomarkers, CSF, diagnosis
in
Alzheimer's and Dementia
volume
21
issue
3
article number
e14528
publisher
Wiley
external identifiers
  • pmid:40042435
  • scopus:86000084045
ISSN
1552-5260
DOI
10.1002/alz.14528
language
English
LU publication?
yes
id
93d241e5-24a3-42d0-a4d1-825da9a3a8d8
date added to LUP
2025-06-24 09:43:42
date last changed
2025-06-25 03:00:08
@article{93d241e5-24a3-42d0-a4d1-825da9a3a8d8,
  abstract     = {{<p>Amyloid-β (Aβ) positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) biomarkers are now established tools in the diagnostic workup of patients with Alzheimer's disease (AD), and their use is anticipated to increase with the introduction of new disease-modifying therapies. Although these biomarkers are comparable alternatives in research settings to determine Aβ status, biomarker testing in clinical practice requires careful consideration of the strengths and limitations of each modality, as well as the specific clinical context, to identify which test is best suited for each patient. This article provides a comprehensive review of the pathologic processes reflected by Aβ-PET and CSF biomarkers, their performance, and their current and future applications and contexts of use. The primary aim is to assist clinicians in making better-informed decisions about the suitability of each biomarker in different clinical situations, thereby reducing the risk of misdiagnosis or incorrect interpretation of biomarker results. Highlights: Recent advances have positioned Aβ PET and CSF biomarkers as pivotal in AD diagnosis. It is crucial to understand the differences in the clinical use of these biomarkers. A team of experts reviewed the state of Aβ PET and CSF markers in clinical settings. Differential features in the clinical application of these biomarkers were reviewed. We discussed the role of Aβ PET and CSF in the context of novel plasma biomarkers.</p>}},
  author       = {{Leuzy, Antoine and Bollack, Ariane and Pellegrino, Daniela and Teunissen, Charlotte E. and La Joie, Renaud and Rabinovici, Gil D. and Franzmeier, Nicolai and Johnson, Keith and Barkhof, Frederik and Shaw, Leslie M. and Arkhipenko, Alexander and Schindler, Suzanne E. and Honig, Lawrence S. and Moscoso Rial, Alexis and Schöll, Michael and Zetterberg, Henrik and Blennow, Kaj and Hansson, Oskar and Farrar, Gill}},
  issn         = {{1552-5260}},
  keywords     = {{Alzheimer; Aβ-PET; biomarkers; CSF; diagnosis}},
  language     = {{eng}},
  number       = {{3}},
  publisher    = {{Wiley}},
  series       = {{Alzheimer's and Dementia}},
  title        = {{Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease}},
  url          = {{http://dx.doi.org/10.1002/alz.14528}},
  doi          = {{10.1002/alz.14528}},
  volume       = {{21}},
  year         = {{2025}},
}